Single Doses News Today

Alnylam Pharmaceuticals, Inc.: Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy

April 26, 2023

Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPa and sAPPß in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date Encouraging Clinical Safety and

United States United Kingdom Bryan Crowe Alexandra Bowie Yvonne Greenstreet Pushkal Garg

Source: finanznachrichten.de

Navigation

Single Doses News Today

Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, ...

Alnylam Pharmaceuticals, Inc.: Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Explore More Categories